Neoadjuvant nivolumab + palbociclib + anastrozole for oestrogen receptor-positive/human epidermal growth factor receptor 2-negative primary breast cancer: Results from CheckMate 7A8

Background: Preclinical data suggest synergistic activity with the combination of programmed death-1 and cyclin-dependent kinase 4/6 blockade in oestrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2–) breast cancer. The noncomparative phase 1b/2 CheckMate 7A8 study (NCT04075...

Cijeli opis

Bibliografski detalji

Glavni autori:	Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruiz-Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M. Tolaney
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-12-01
Serija:	Breast
Teme:	Anastrozole Aromatase inhibitors Breast neoplasms Cyclin-dependent kinases Immune checkpoint inhibitors Neoadjuvant therapy
Online pristup:	http://www.sciencedirect.com/science/article/pii/S0960977623005544
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!